ObsEva

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GENEVA, Switzerland and BOSTON, MA (February 10, 2021) – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today provided a corporate update, including its roadmap for advancing its clinical programs in 2021.

ObsEva Provides Business Outlook for 2021

American Battery Technology Company

Guardion Health Sciences Inc

Safe Bulkers

IsoRay

Zomedica

There's an old saying that 'gaps refill'. And that means that these 7 penny stock Bubbles may be about to burst.

7 Penny Stock Bubbles That Are About to Burst

Amphastar Pharma

Evoqua Water Technologies

Barings BDC Inc

Biohaven Pharmaceutical Hld

Colfax

Crh Medical

Global Blood Therapeutics

Hannon Armstrong Sustainable Infrastructure Capital

Houghton Mifflin Harcourt

Lexicon Pharmaceuticals

MannKind

Nektar Therapeutics

Nano-X Imaging

Personalis Inc

PIMCO Corporate & Income Opportunity Fund

Construction Partners

Surgery Partners

SP Plus

Takeda Pharmaceutical

Cohen & Steers Infrastructure Fund Inc

Xerium Technologies

A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions.

Final Update For My 20/20 Vision For 2020 Dividend Paying Stocks

Investors need to pay close attention to ObsEva (OBSV) stock based on the movements in the options market lately.

Implied Volatility Surging for ObsEva (OBSV) Stock Options

The stock price of Obseva SA (NASDAQ: OBSV) has increased by 61.51% on Friday, January 15. This is why it happened.

OBSV Stock Price Increased 61.51%: Why It Happened

ObsEva (OBSV) stock is soaring higher on Friday as shares see heavy trading despite there not being any noteworthy news today. The post OBSV Stock: 7 Things for ObsEva Investors to Know Before Investing in the Penny Stock appeared first on InvestorPlace.

OBSV Stock: 7 Things for ObsEva Investors to Know Before Investing in the Penny Stock

Aphria

JPMorgan Chase & Co

Lockheed Martin

Newmont Mining

Star Peak Energy Transition Corp

In the last round, 36% of recipients saved the money, If you're planning the same with the second payment, here are seven stocks to buy with your stimulus check. The post 7 Stocks to Buy With That Second Stimulus Check As More Plan to Save It appeared first on InvestorPlace.

7 Stocks to Buy With That Second Stimulus Check As More Plan to Save It

European Medicines Agency Validates Yselty MAA for Uterine Fibroids; US NDA Planned for 1H 2021

ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program

Geneva, Switzerland and Boston, MA – January 7, 2021 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that Company Management will be participating in the JP Morgan Virtual Healthcare Conference taking place January 11-14, 2021. ObsEva will present on Thursday, January 14, 2021 at 7:30 a.m. Eastern Time (ET).

ObsEva SA to Participate in JP Morgan Virtual Healthcare Conference January 11 - 14, 2021

Geneva, Switzerland and Boston, MA – January 4, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced the appointment of David Renas as Chief Financial Officer (CFO) and member of the company's Executive Committee, effective today. He will be based in the U.S.

ObsEva appoints David Renas as Chief Financial Officer

 PRIMROSE 1 52-week results confirm the sustained efficacy and continued safety of linzagolix (Yselty®), with a potential best-in-class high-dose option (200 mg with add-back therapy [ABT])

ObsEva Announces Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids

Geneva, Switzerland and Boston, MA – December 1, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health today announced that Ernest Loumaye, MD, PhD, co-founder and member of the Board of Directors, will give a presentation at the ISGE (International Society of Gynecological Endocrinology) 19th World Congress Virtual Edition, December 2-5, 2020.

ObsEva SA to present at The International Society of Gynecological Endocrinology 19th World Congress – virtual edition, December 2-5, 2020

ObsEva (OBSV) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

ObsEva (OBSV) Catches Eye: Stock Jumps 5.1%

If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options for the management of uterine fibroids

ObsEva SA Submits Marketing Authorization Application to the European Medicines Agency for YSELTY® (linzagolix) for the Treatment of Women with Uterine Fibroids

Over 50% reduction of pre-term delivery within 48hrs of treatment in singleton pregnancy

ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor

Geneva, Switzerland and Boston, MA – November 13, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health today announced that Company Management will present an update on the Company and its pipeline at the 11th Annual Jefferies (Virtual) London Healthcare Conference, taking place November 17 - 19, 2020.

ObsEva SA to present at Jefferies Virtual London Healthcare Conference, November 17 – 19, 2020

 Geneva, Switzerland and Boston, MA – November 9, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health today announced that ObsEva's Board of Directors has appointed Brian O'Callaghan, to succeed Dr Ernest Loumaye, as Chief Executive Officer and member of the company's Executive Committee, effective 1 December 2020. He will also be proposed for election on ObsEva's Board of Directors at next company AGM.

ObsEva appoints Brian O'Callaghan as Chief Executive Officer

 Geneva, Switzerland and Boston, MA – 2 November, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced an oral communication and a live symposium at SEUD Online Week 2020 to take place November 3 – 6.

ObsEva SA hosts live symposium and presents oral communication at the SEUD Online Week November 3 - 6, 2020

 Geneva, Switzerland and Boston, MA – October 22, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced the presentation of two posters at the ASRM 2020 Virtual Scientific Congress and Expo during the first ever Late-Breaking Abstract Poster Session.

ObsEva SA Presented Two Late-Breaking Posters at the ASRM 2020 Virtual Scientific Congress October 17-21

Geneva, Switzerland and Boston, MA – October 20, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced the presentation of a poster at the ASRM 2020 Virtual Scientific Congress and Expo. 

ObsEva SA Presented Nolasiban Poster at the ASRM 2020 Virtual Scientific Congress October 17-21

 ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that CEO Ernest Loumaye will present an update on the Company and its pipeline at the H.C Wainwright 22nd Annual Global Investment Virtual Conference taking place September 14-16, 2020.

ObsEva SA to present at the H.C Wainwright 22nd Annual Global Investment  Virtual Conference, September 14-16, 2020

 GENEVA, Switzerland and BOSTON, MA (September 3, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN) (“ObsEva” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the pricing of an underwritten equity offering and concurrent private placement transaction.

ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement  Priced At-The-Market of Common Shares and 15-Month Purchase Warrants for  Potential Additional Gross Proceeds of $23.9 Million

 Geneva, Switzerland and Boston, MA –  August 7, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that CEO Ernest Loumaye will present an update on the Company and its pipeline at the Wedbush PacGrow Virtual Healthcare Conference taking place August 11 - 12, 2020.

ObsEva SA to present at the Wedbush PacGrow Healthcare Virtual Conference, August 11 – 12, 2020

 Primary endpoint successfully met in Phase 3 PRIMROSE 1 trial of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids

ObsEva Announces Second Quarter 2020 Financial Results and Business Update

 Geneva, Switzerland and Boston, MA – July 15, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced winning the Clinical Science Award for Oral Presentation at the ESHRE Virtual 36th Annual Meeting, which took place July  5-8, 2020. The Award was presented to the first and presenting author of the best oral presentation on a clinical science topic.

News for ObsEva Stock (OBSV)